Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
Condition: Renal Cell Carcinoma Interventions: Drug: Nivolumab; Drug: Ipilimumab Sponsor: Kidney Cancer Research Bureau Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Research | Urology & Nephrology | Yervoy